Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver in non–small cell lung cancer (NSCLC). Alectinib, a highly selective second-generation ALK inhibitor, has demonstrated remarkable clinical efficacy; however, its potential influence on postoperative wound healing remains unclear. We report the case of a 42-year-old male with ALK-positive poorly differentiated lung adenocarcinoma who underwent right lower lobectomy following significant tumor regression with alectinib therapy. Postoperatively, the patient developed delayed wound healing complicated by Staphylococcus aureus infection. After temporary discontinuation of alectinib combined with repeated debridement, negative pressure wound therapy, and wound closure, the lesion achieved complete healing. This case highlights the possibility that alectinib may impair postoperative wound repair. Comprehensive perioperative drug evaluation, multidisciplinary collaboration, and carefully monitored treatment interruption are recommended to maintain the balance between oncologic control and effective tissue healing.
He et al. (Fri,) studied this question.